TLR4 and cancer: With respect to the immune system, RFX1 acts as an activator of MHC Class II genes and represses MCP1, CD11a, CD70, IL17A, TLR4, and the TGFβ2 expressions, which could be instrumental in understanding etiology and materializing treatment strategies for cancer and other immune-related disorders.